¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"drug development pathway"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • drug abstinence
    ¾à¹°±Ý´Ü
  • drug abuse
    ¾à¹°³²¿ë
  • drug acne
    ¾à¹°¿©µå¸§
  • drug addiction
    ¾à¹°Áßµ¶, ¾à¹°Å½´Ð
  • drug adjuvant
    ¾à¹°º¸Á¶Á¦, º¸Á¶¾à¹°
  • drug adsorption
    ¾à¹°ÈíÂø
  • drug allergy
    ¾à¹°¾Ë·¹¸£±â
  • drug delivery system
    ¾à¹°Àü´Þü°è
  • drug dependence
    ¾à¹°ÀÇÁ¸
  • drug dispensing
    ¾à¹°Á¶Á¦
  • drug eruption
    ¾à¹°¹ßÁø, ¾àÁø
  • drug idiosyncrasy
    ¾à¹°Æ¯ÀÌüÁú
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • drug interference
    ¾à¹°°£¼·
  • drug intoxication
    ¾à¹°Áßµ¶
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
  • arsenic drug
    ºñ¼Ò¾à
  • autonomic drug
    ÀÚÀ²½Å°æ¾à
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • drug abstinence
    ¾à¹°±Ý´Ü, ±Ý´Ü
  • drug abuse
    ¾à¹°³²¿ë
  • drug acne
    ¾à¹°¿©µå¸§
  • drug addiction
    ¾à¹°Áßµ¶
  • drug adjuvant
    ÀǾàǰ÷°¡¹°
  • drug adsorption
    ¾à¹°ÈíÂø
  • drug allergy
    ¾à¹°¾Ë·¹¸£±â
  • drug-induced hemolytic anemia
    ¾à¹°À¯¹ß¿ëÇ÷ºóÇ÷
  • new drug application
    ½Å¾àÇã°¡½Åû
  • drug resistant bacterium
    ¾àÁ¦³»¼º±Õ
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • hematological drug
    Ç÷¾×ÀÛ¿ë¾à(úìäûíÂéÄå·).
  • hydrophilic drug
    Ä£¼ö¼º ¾àÁ¦.
  • ideosyncratic drug response
    ƯÀ̼º ¾à¹° ¹ÝÀÀ
  • photoallergic drug eruption
    ±¤¾Ë·¹¸£±â¼º ¾àÁø
  • prescription drug
    󹿾à.
  • pressor drug
    Ç÷¾Ð»ó½ÂÁ¦.
  • prolonged action drug
    Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • prolonged action drug
    Ưȿ¼º ¾àÁ¦(÷åüùàõå·ð¥), Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • psychedelic drug
    ȯ°¢Á¦
  • psychoactive drug
    Á¤½ÅȰ¼º ¾à¹°(?)
  • psychoactive drug
    Á¤½ÅȰ¼ºÁ¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • metabolic pathway
    ´ë»ç°æ·Î.
  • neurohumoral pathway
    ½Å°æ¾×¼º °æ·Î(~ÌèÖØ).
  • nigrostriatal pathway
  • oculomotor pathway
    ¾È±¸¿îµ¿½Å°æ·Î(äÑÏ¹ê¡ ÔÑãêÌèÖØ).
  • optic pathway
    ½Ã·Î.
  • optic pathway
    ½Ã½Å°æ·Î.
  • pain pathway
    Åë°¢Àü´Þ·Î(÷ÔÊÆîîÓ¹ÖØ).
  • pancreas,protein secertion pathway
    ´Ü¹éÁúºÐºñ°æ·Î(Ó±ÛÜòõÝÂÝôÌèÖØ)
  • parallel pathway
    (°¨°¢Á¤º¸Ã³¸®ÀÇ)ÆòÇà°æ·Î
  • pathway
    °æ·Î(ÌèÖØ).
  • pentose phosphate pathway
    ¿Àź´ç ÀλêÈ­ ¹ÝÀÀ
  • phosphogluconate oxidative pathway
    ±Û·çÄÜ»ê»êÈ­°æ·Î, ÀÎ´ç¿ø»êÈ­°æ·Î(ìÝÓØ ê«ß«ûùÌèÖØ).
  • proximal common pathway
    ±ÙÀ§°øÅë°æ·Î.
  • pyruvate pathway
    ÇÇ·çºê»ê¿°´ë»ç°æ·Î(¡­ß«ç¤ÓÛÞóÌèÖØ).
  • reflex path =r. pathway, r. tract
    ¹Ý»ç°æ·Î(ÚãÞÒÌèÖØ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Warburg-Dickens pathway
    ¹Ù¸£ºÎ¸£Å©-µðŲ½º °æ·Î(ÌèÖØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
FCP F-cell production; final common pathway; Functional Communication Profile
HMP hexose monophosphate pathway; hot moist packs
MAP malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ...
PAP pancreatitis-associated protein; Papanicolaou [test]; papaverine; passive-aggressive personality; pa...
PBP penicillin-binding protein; porphyrin biosynthesis pathway; prostate-binding protein; pseudobulbar p...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ICDS Integrated Child Development Service
MCD Malformations of Cortical Development
MGDF Megakaryocyte Growth and Development Factor
MDI Mental Development Index
NCDS National Child Development Study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antiemetic drug
    ÁøÅäÁ¦, Ç×±¸ÅäÁ¦
  • antifungal drug
    Ç×Áø±ÕÁ¦
    Áø±ÕÀÇ ¹ø½Ä°ú ¹ßÀ°À» ¾ïÁ¦ ¶Ç´Â ÀúÁöÇÏ´Â ¹°Áú, ÀÎÀÚ.
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹Î ¾à
    È÷½ºÅ¸¹Î ÀÛ¿ë¿¡ ±æÇ×ÇÏ´Â ¾à¹°.
  • antiinflammatory drug
    ¼Ò¿°Á¦
  • antimalarial drug
    Ç׸»¶ó¸®¾ÆÁ¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇ ¾à
  • antipsychotic drug
    Ç×Á¤½Åº´ ¾à, ÇâÁ¤½Åº´ ¾à¹°
  • antiseborrheic drug
    Ç×Áö·ç ¾à
  • antispirochetal drug
    Ç×½ºÇÇ·ÎÇìŸ ¾à
  • antithyroid drug
    Ç×°©»ó¼± ¾à
  • bioreductive drug
    »ýü ȯ¿ø¼º ¾àÁ¦
  • bullous drug-induced exanthema
    ¾à¹°¿¡ ÀÇÇÑ ¼öÆ÷¼º ¹ßÁø
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
  • cholinergic drug
    Äݸ° ÀÛ¿ë ¾à
  • common drug
    º¸Åë ¾à
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
lysogenic pathway <virology> The method by which a virus becomes a dormant, passive part of its host bacterium's genome (a lysogenic virus), choosing to insert its DNA into the host's and postponing completion of its lytic cycle, at which time it destroys the host and spreads its progeny to infect other bacterial cells (enters the lytic pathway).
(09 Oct 1997)
lytic pathway The steps in the method that a virus takes to complete a lytic cycle, including the production and assembly of progeny viruses with host cell machinery and the destruction of the host cell by rupturing its plasma membrane (lysis), releasing the progeny viruses in the process.
(09 Oct 1997)
abnormalities, drug-induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
(12 Dec 1998)
activity, drug A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa).
(12 Dec 1998)
addictive drug Any drug that creates a certain degree of euphoria and has a strong potential for addiction.
(05 Mar 2000)
adverse drug reaction reporting systems Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
(12 Dec 1998)
akathisia, drug-induced Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation).
(12 Dec 1998)
antineoplastic drug A drug that stops or slows the maturation and spread of tumour cells (benign or malignant).
(09 Oct 1997)
maintenance drug therapy In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
rational drug design <pharmacology> Modeling the molecular structure of the target of a drug, for example, an antigen, and then designing a drug that will attack it.
(17 Dec 1997)
receptors, drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behaviour of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified.
(12 Dec 1998)
recreational drug A controlled substance taken for non-medical purposes. Street drugs comprise various amphetamines, anaesthetics, barbiturates, opiates, and psychoactive drugs, and many are derived from natural sources (e.g., the plants Papaver somniferum, Cannibis sativa, Amanita pantherina, Lophophora williamsii). Slang names include acid (lysergic acid diethylamide), angel dust (phencyclidine), coke (cocaine), downers (barbiturates), grass (marijuana), hash (concentrated tetrahydrocannibinol), magic mushrooms (psilocybin), mescaline (peyote), speed (amphetamines). During the 1980s, a new class of "designer drugs" arose, mostly analogs of psychoactive substances intended to escape regulation under the Controlled Substances Act. Also, crack cocaine, a potent, smokable form of cocaine, emerged as a major public health problem. In the U.S. Illicit use of drugs such as cocaine, marijuana, and heroin historically has occurred in cycles.
Synonym: recreational drug.
(05 Mar 2000)
peak plasma drug concentration <pharmacology> The highest level of drug that can be obtained in the blood usually following multiple doses.
(09 Oct 1997)
chemotherapy drug sensitivity test <investigation> A test to assess a cancerous tissue's response and vulnerability to chemotherapy drugs. This test can help predict a patients response to treatment and suggest which drugs may be useful.
(16 Dec 1997)
metabolic detoxication, drug Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á